FIL Ltd lessened its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,084,204 shares of the specialty pharmaceutical company’s stock after selling 119,177 shares during the period. FIL Ltd owned about 1.81% of Jazz Pharmaceuticals PLC worth $168,593,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the stock. FMR LLC increased its holdings in Jazz Pharmaceuticals PLC by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after purchasing an additional 849,348 shares during the period. Vanguard Group Inc. increased its holdings in Jazz Pharmaceuticals PLC by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after purchasing an additional 153,908 shares during the period. Northern Trust Corp increased its holdings in Jazz Pharmaceuticals PLC by 1.6% during the 2nd quarter. Northern Trust Corp now owns 221,697 shares of the specialty pharmaceutical company’s stock valued at $34,474,000 after purchasing an additional 3,396 shares during the period. UBS Asset Management Americas Inc. increased its holdings in Jazz Pharmaceuticals PLC by 4.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 145,771 shares of the specialty pharmaceutical company’s stock valued at $22,667,000 after purchasing an additional 6,805 shares during the period. Finally, Quantitative Investment Management LLC purchased a new position in Jazz Pharmaceuticals PLC during the 2nd quarter valued at about $3,016,000. Institutional investors own 88.24% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Shares Sold by FIL Ltd” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://sportsperspectives.com/2017/09/21/jazz-pharmaceuticals-plc-jazz-shares-sold-by-fil-ltd.html.
Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 0.17% during mid-day trading on Thursday, hitting $147.82. The stock had a trading volume of 43,838 shares. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The company’s 50 day moving average is $148.82 and its 200-day moving average is $150.52. The stock has a market cap of $8.88 billion, a P/E ratio of 22.77 and a beta of 1.13.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The business had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.67 earnings per share. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current fiscal year.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,717 shares of company stock worth $1,346,617. 4.30% of the stock is currently owned by corporate insiders.
A number of research analysts recently issued reports on JAZZ shares. Mizuho reduced their price target on Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating on the stock in a report on Wednesday, May 31st. Vetr upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target on the stock in a report on Tuesday, June 6th. Cowen and Company restated an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Piper Jaffray Companies restated an “overweight” rating and set a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, BMO Capital Markets boosted their price target on Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $180.96.
Jazz Pharmaceuticals PLC Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.